What is Biodesix, Inc.'s SG&A?

Biodesix, Inc. (BDSX) reported SG&A of $24.26M in Q1 2026.

How has Biodesix, Inc.'s SG&A changed year-over-year?

Biodesix, Inc.'s SG&A increased by 18.6% year-over-year, from $20.45M to $24.26M.

What is the long-term trend for Biodesix, Inc.'s SG&A?

Over 4 years (2021 to 2025), Biodesix, Inc.'s SG&A has grown at a 14.7% compound annual growth rate (CAGR), from $50.52M to $87.55M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Biodesix, Inc. BDSX SG&A

SG&A at other companies

Personalis, Inc.PSNL

$17.9M+46.0%

Tempus AI, Inc.TEM

$212.59M+37.5%

GeneDx HoldingsWGS

$74.59M+47.9%

Bio-Rad LaboratoriesBIO

$212.4M+1.7%

Quest DiagnosticsDGX

$504M+5.9%

Charles River LaboratoriesCRL

$159.42M-10.3%

Other financials

Income statement

See full

Revenue$25.6M+42.3%

Operating income-$6.2M+32.1%

Net income-$7.8M+29.8%

EPS (diluted)-$0.81+46.7%

Balance sheet

See full

Cash & equivalents$25.6M+45.3%

Total debt$71.6M+15.0%

Total equity$9.1M-17.4%

Total assets$94.6M+9.7%

Cash flow

See full

Operating cash flow-$10.2M-18.2%

CapEx$81.0K+9.5%

Free cash flow-$10.2M-18.1%

Valuation

See full

Market cap$233.52M+476%

Enterprise value$279.56M+204%

P/S2.4×+1.9×

Profitability

See full

Operating margin-26%-7.5pp

Net margin-33.3%-9.3pp

FCF margin-26.8%-9.6pp

Returns & leverage

See full

Return on equity-316.5%—

Debt / equity7.8×+2.2×

Current ratio2.8×+0.6×

Where this comes from

Reported directly by Biodesix, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Biodesix, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biodesix, Inc.'s sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Biodesix, Inc.'s SG&A?: Biodesix, Inc. (BDSX) reported SG&A of $24.26M in Q1 2026.
How has Biodesix, Inc.'s SG&A changed year-over-year?: Biodesix, Inc.'s SG&A increased by 18.6% year-over-year, from $20.45M to $24.26M.
What is the long-term trend for Biodesix, Inc.'s SG&A?: Over 4 years (2021 to 2025), Biodesix, Inc.'s SG&A has grown at a 14.7% compound annual growth rate (CAGR), from $50.52M to $87.55M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.